(Q33611922)

28 July 2017

1 reference

title

Current drug therapy for multiple myeloma (English)

1 reference

28 July 2017

Huang YW

1

1 reference

28 July 2017

Hamilton A

2

1 reference

28 July 2017

Arnuk OJ

3

1 reference

28 July 2017

Chaftari P

4

1 reference

28 July 2017

Chemaly R

5

1 reference

28 July 2017

publication date

1 April 1999

1 reference

28 July 2017

1 reference

28 July 2017

volume

57

1 reference

28 July 2017

issue

4

1 reference

28 July 2017

page(s)

485-506

1 reference

Autologous bone marrow transplantation with immunotoxin purged marrow for multiple myeloma. Long term results in 14 patients with advanced disease

28 July 2017

cites work

1 reference

12 December 2020

Gallium nitrate for the treatment of bone metastases

1 reference

12 December 2020

Cancer statistics, 1998.

1 reference

12 December 2020

Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities

1 reference

12 December 2020

CALLA-positive myeloma: an aggressive subtype with poor survival

1 reference

12 December 2020

A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study

1 reference

12 December 2020

Karyotype in multiple myeloma and plasma cell leukaemia

1 reference

12 December 2020

Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy

1 reference

12 December 2020

Graft-versus-myeloma effect in two cases

1 reference

12 December 2020

Pathophysiology and management of bone disease in multiple myeloma

1 reference

12 December 2020

Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia

1 reference

12 December 2020

Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4-hydroperoxycyclophosphamide

1 reference

12 December 2020

Diagnosis, prognosis, and standard treatment of multiple myeloma

1 reference

12 December 2020

Dexamethasone, cyclophosphamide, idarubicin and etoposide (DC-IE): a novel, intensive induction chemotherapy regimen for patients with high-risk multiple myeloma

1 reference

12 December 2020

Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants

1 reference

12 December 2020

Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

1 reference

12 December 2020

High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma

1 reference

12 December 2020

Oral dosage of melphalan and response to treatment in multiple myeloma

1 reference

12 December 2020

Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma

1 reference

12 December 2020

Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma

1 reference

12 December 2020

Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma

1 reference

12 December 2020

Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma

1 reference

12 December 2020

Magnetic resonance imaging of the bone marrow in hematologic malignancies.

1 reference

12 December 2020

Multiple myeloma: increased circulating lymphocytes carrying plasma cell-associated antigens as an indicator of poor survival

1 reference

12 December 2020

Anti-CD54 (ICAM-1) has antitumor activity in SCID mice with human myeloma cells.

1 reference

12 December 2020

Newer approaches to the therapy of multiple myeloma

1 reference

12 December 2020

Clinical results of recombinant erythropoietin in transfusion-dependent patients with refractory multiple myeloma: role of cytokines and monitoring of erythropoiesis

1 reference

12 December 2020

Myeloma VL and VH gene sequences reveal a complementary imprint of antigen selection in tumor cells.

1 reference

12 December 2020

A prospective, controlled, nonrandomized study on prophylactic parenteral dichloromethylene bisphosphonate (clodronate) in multiple-myeloma

1 reference

12 December 2020

Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP

1 reference

12 December 2020

Biology and therapy of multiple myeloma in 1996.

1 reference

12 December 2020

Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24

1 reference

12 December 2020

High serum IL-2 levels are predictive of prolonged survival in multiple myeloma.

1 reference

12 December 2020

Multiple myeloma: prognosis and standard treatment

1 reference

12 December 2020

Smoldering multiple myeloma

1 reference

12 December 2020

Standard treatment of multiple myeloma

1 reference

12 December 2020

Treatment of multiple myeloma with etidronate: results of a multicentre double-blind study. Groupe d'Etudes et de Recherches sur le Myélome (GERM)

1 reference

12 December 2020

Autotransplants in multiple myeloma: pushing the envelope

1 reference

12 December 2020

Bone marrow transplantation in multiple myeloma

1 reference

12 December 2020

Combined recombinant human interferon alpha 2 and cytotoxic agents studied in a clonogenic assay

1 reference

12 December 2020

Clinical research update: zoledronate

1 reference

12 December 2020

Comparison of myeloma cell contamination of bone marrow and peripheral blood stem cell harvests

1 reference

12 December 2020

Multiple myeloma: reduced plasma cell contamination in peripheral blood progenitor cell collections performed after repeated high-dose chemotherapy courses

1 reference

12 December 2020

Interleukin-6 fused to a mutant form of Pseudomonas exotoxin kills malignant cells from patients with multiple myeloma

1 reference

12 December 2020

Plasma cell dyscrasias

1 reference

12 December 2020

Localization of Kaposi's sarcoma-associated herpesvirus in bone marrow biopsy samples from patients with multiple myeloma.

1 reference

12 December 2020

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.

1 reference

12 December 2020

Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study

1 reference

12 December 2020

1 reference

12 December 2020

Graft-versus-myeloma effect: proof of principle

1 reference

12 December 2020

New insights in the clinical biology of multiple myeloma

1 reference

12 December 2020

Hypercalcemia: mechanisms, differential diagnosis, and remedies

1 reference

12 December 2020

Intensive treatment strategies in multiple myeloma

1 reference

12 December 2020

Peripheral blood progenitor cell transplantation in multiple myeloma following high-dose melphalan-based therapy.

1 reference

12 December 2020

The Chemotherapy of Plasma-Cell Myeloma and the Incidence of Acute Leukemia

1 reference

12 December 2020

Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation

1 reference

12 December 2020

Cytogenetics and molecular genetics in multiple myeloma

1 reference

12 December 2020

Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6.

1 reference

12 December 2020

High-dose glucocorticoid treatment of resistant myeloma

1 reference

12 December 2020

Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma

1 reference

12 December 2020

Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma.

1 reference

12 December 2020

Evaluation of CD38 as target for immunotherapy in multiple myeloma

1 reference

12 December 2020

Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma.

1 reference

12 December 2020

Comparison of marrow vs blood-derived stem cells for autografting in previously untreated multiple myeloma

1 reference

12 December 2020

Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.

1 reference

12 December 2020

Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group

1 reference

12 December 2020

Multiple myeloma: review of 869 cases

1 reference

12 December 2020

Renal failure in multiple myeloma. A study of the presenting findings, response to treatment and prognosis in 26 patients

1 reference

12 December 2020

Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma

1 reference

12 December 2020

Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults

1 reference

12 December 2020

Expression of Fas/Apo-1 (CD95) and apoptosis in tumor cells from patients with plasma cell disorders

1 reference

12 December 2020

Intensive chemotherapy with blood progenitor transplantation for primary resistant multiple myeloma.

1 reference

12 December 2020

Multiple myeloma: significance of plasmablastic subtype in morphological classification

1 reference

12 December 2020

The efficacy and toxicity of VAD in the treatment of myeloma and related disorders

1 reference

12 December 2020

Idiotype-specific T cells in multiple myeloma: targets for an immunotherapeutic intervention?

1 reference

12 December 2020

Low-dose recombinant interleukin-2 therapy in advanced multiple myeloma

1 reference

12 December 2020

Gallium nitrate for acute treatment of cancer-related hypercalcemia. A randomized, double-blind comparison to calcitonin

1 reference

12 December 2020

Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens

1 reference

12 December 2020

Pharmacologic approaches to reversing multidrug resistance.

1 reference

12 December 2020

Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.

1 reference

12 December 2020

Interleukin-6 is a prognostic factor in multiple myeloma

1 reference

12 December 2020

Double-intensive therapy in high-risk multiple myeloma.

1 reference

12 December 2020

Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study

1 reference

12 December 2020

Bisphosphonates in multiple myeloma: current status; future perspectives

1 reference

12 December 2020

The use of dichloromethylene diphosphonate for the management of hypercalcaemia in multiple myeloma

1 reference

12 December 2020

Oral melphalan pharmacokinetics--relation to dose in patients with multiple myeloma

1 reference

12 December 2020

Australian Leukaemia Study Group myeloma II: a randomized trial of intensive combination chemotherapy with or without interferon in patients with myeloma.

1 reference

12 December 2020

Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma

1 reference

12 December 2020

Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients

1 reference

12 December 2020

Peripheral blood stem cell transplantation in a multiple myeloma patient with end-stage renal failure

1 reference

12 December 2020

A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results

1 reference

12 December 2020

The biology and clinical uses of blood stem cells.

1 reference

12 December 2020

Interleukin-6 prevents dexamethasone-induced myeloma cell death.

1 reference

12 December 2020

Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor

1 reference

12 December 2020

Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study.

1 reference

12 December 2020

Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

New drug therapy of amyloidoses: resorption of AL-type deposits with 4'-iodo-4'-deoxydoxorubicin

1 reference

12 December 2020

Myeloma biology and therapy. Present status and future developments

1 reference

12 December 2020

A randomized study of VAD therapy with either concurrent or maintenance interferon in patients with newly diagnosed multiple myeloma.

1 reference

12 December 2020

Interferon alfa-2b in the treatment of chronic granulocytic leukemia

1 reference

12 December 2020

Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study

1 reference

12 December 2020

Effect of daily etidronate on the osteolysis of multiple myeloma

1 reference

12 December 2020

Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients.

1 reference

12 December 2020

The role of biotherapies (interleukins, interferons and erythropoietin) in multiple myeloma

1 reference

12 December 2020

Advances in the treatment of multiple myeloma

1 reference

12 December 2020

Allogeneic stem cell transplantation for multiple myeloma

1 reference

12 December 2020

Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death

1 reference

12 December 2020

Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia

1 reference

12 December 2020

Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma

1 reference

12 December 2020

A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia

1 reference

12 December 2020

Generation of virtually pure and potentially proliferating dendritic cells from non-CD34 apheresis cells from patients with multiple myeloma

1 reference

12 December 2020

Ibandronate in oncology

1 reference

12 December 2020

New xenograft model of multiple myeloma and efficacy of a humanized antibody against human interleukin-6 receptor.

1 reference

12 December 2020

High-dose busulfan in patients with myeloma

1 reference

12 December 2020

Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden

1 reference

12 December 2020

Cyclophosphamide and etoposide therapy with GM-CSF for VAD-resistant multiple myeloma.

1 reference

12 December 2020

The treatment of multiple myeloma

1 reference

12 December 2020

Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON

1 reference

12 December 2020

Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on autologous transplantation in multiple myeloma

1 reference

12 December 2020

Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma

1 reference

12 December 2020

Clinical Studies with Modulators of Multidrug Resistance

1 reference

12 December 2020

Treatment of the hypercalcaemia of malignancy with intravenous clodronate.

1 reference

12 December 2020

Intensive combined therapy for previously untreated aggressive myeloma

1 reference

12 December 2020

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

1 reference

12 December 2020

Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy

1 reference

12 December 2020

Localized and indolent myeloma

1 reference

12 December 2020

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

1 reference

12 December 2020

Multiple myeloma: increasing evidence for a multistep transformation process

1 reference

12 December 2020

Alpha-2a-interferon/melphalan/prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma

1 reference

12 December 2020

Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group

1 reference

12 December 2020

Drug resistance in multiple myeloma

1 reference

12 December 2020

Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914).

1 reference

12 December 2020

Prognostic factors with high-dose melphalan for refractory multiple myeloma.

1 reference

12 December 2020

Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.

1 reference

12 December 2020

Alpha-interferon combination therapy of resistant myeloma

1 reference

12 December 2020

Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study

1 reference

12 December 2020

Bisphosphonates in multiple myeloma

1 reference

12 December 2020

Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials

1 reference

12 December 2020

Use a gentle approach for refractory myeloma patients

1 reference

12 December 2020

Treatment of primary amyloidosis.

1 reference

12 December 2020

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

12 December 2020

Phase I-II study of busulfan and cyclophosphamide conditioning for transplantation in advanced multiple myeloma

1 reference

12 December 2020

Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo

1 reference

12 December 2020

Combination chemotherapy with vincristine, doxorubicin, dexamethasone for refractory or relapsing multiple myeloma

1 reference

12 December 2020

Immunotherapy of multiple myeloma

1 reference

12 December 2020

Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Cooperative Study Group

1 reference

12 December 2020

The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis

1 reference

12 December 2020

A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group

1 reference

12 December 2020

Effective treatment of advanced multiple myeloma refractory to alkylating agents.

1 reference

12 December 2020

Pathogenesis and management of bone lesions in multiple myeloma

1 reference

12 December 2020

Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma

1 reference

12 December 2020

In vitro effect of GF120918, a novel reversal agent of multidrug resistance, on acute leukemia and multiple myeloma cells

1 reference

12 December 2020

"Benign" monoclonal gammopathy--after 20 to 35 years of follow-up

1 reference

12 December 2020

A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study

1 reference

12 December 2020

Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol

1 reference

12 December 2020

Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma

1 reference

12 December 2020

Autoregulatory circuits in myeloma. Tumor cell cytotoxicity mediated by soluble CD16.

1 reference

12 December 2020

Early myeloablative therapy for multiple myeloma.

1 reference

12 December 2020

Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion

1 reference

12 December 2020

High-dose melphalan for multiple myeloma: long-term follow-up data

1 reference

12 December 2020

1 reference

12 December 2020

Multiple myeloma: clinical evaluation of plasma cell lymphoproliferative disorders and initial management

1 reference

12 December 2020

Primary dexamethasone treatment of multiple myeloma

1 reference

12 December 2020

Overview of bisphosphonates

1 reference

12 December 2020

Autotransplants in multiple myeloma: what have we learned?

1 reference

12 December 2020

Standard therapy versus autologous transplantation in multiple myeloma

1 reference

12 December 2020

The role of interferon-alpha in the management of myelomatosis

1 reference

12 December 2020

Low-dose gallium nitrate for prevention of osteolysis in myeloma: results of a pilot randomized study.

1 reference

12 December 2020

Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma

1 reference

12 December 2020

VAD-based regimens as primary treatment for multiple myeloma

1 reference

12 December 2020

10.2165/00003495-199957040-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

28 July 2017

1002389138

0 references

1 reference